Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.

Stubbs MC, Burn TC, Sparks RB, Maduskuie T, Diamond S, Rupar M, Wen X, Volgina A, Zolotarjova N, Waeltz P, Favata M, Jalluri R, Liu H, Liu XM, Li J, Collins R, Falahatpisheh N, Polam P, DiMatteo D, Feldman P, Dostalik V, Thekkat P, Gardiner C, He X, Li Y, Covington M, Wynn R, Ruggeri B, Yeleswaram S, Xue C, Yao W, Combs AP, Huber R, Hollis G, Scherle P, Liu P.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.0098.2018. doi: 10.1158/1078-0432.CCR-18-0098. [Epub ahead of print]

PMID:
30206163
2.

Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).

Stubbs MC, Krivtsov AV.

Curr Protoc Pharmacol. 2017 Sep 11;78:14.42.1-14.42.19. doi: 10.1002/cpph.28.

3.

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA.

Clin Cancer Res. 2015 May 15;21(10):2348-58. doi: 10.1158/1078-0432.CCR-14-1290. Epub 2015 Feb 16.

4.

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.

Leukemia. 2013 Apr;27(4):852-60. doi: 10.1038/leu.2012.363. Epub 2012 Dec 13.

5.

HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA.

Blood. 2009 Mar 12;113(11):2375-85. doi: 10.1182/blood-2007-09-113597. Epub 2008 Dec 3.

6.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.

Leukemia. 2008 Jan;22(1):66-77. Epub 2007 Sep 13.

7.

FLT3 as a therapeutic target in childhood acute leukemia.

Stubbs MC, Armstrong SA.

Curr Drug Targets. 2007 Jun;8(6):703-14. Review.

PMID:
17584026
8.

Therapeutic implications of leukemia stem cell development.

Stubbs MC, Armstrong SA.

Clin Cancer Res. 2007 Jun 15;13(12):3439-42. Review.

9.

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA.

Nature. 2006 Aug 17;442(7104):818-22. Epub 2006 Jul 16.

PMID:
16862118
11.

The ZF87/MAZ transcription factor functions as a growth suppressor in fibroblasts.

Stubbs MC, Min I, Izzo MW, Rallapalli R, Derfoul A, Hall DJ.

Biochem Cell Biol. 2000;78(4):477-85.

PMID:
11012087
12.

Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ.

Izzo MW, Strachan GD, Stubbs MC, Hall DJ.

J Biol Chem. 1999 Jul 2;274(27):19498-506.

13.

An early S phase checkpoint is regulated by the E2F1 transcription factor.

Stubbs MC, Strachan GD, Hall DJ.

Biochem Biophys Res Commun. 1999 Apr 29;258(1):77-80.

PMID:
10222238
14.
15.

Ten-year analysis of duration of hospitalization of disabled patients.

Vallbona C, Gotcher SB, Libman C, Spencer WA, Stubbs MC.

Med Care. 1970 Nov-Dec;8(6):488-500. No abstract available.

PMID:
4249903

Supplemental Content

Loading ...
Support Center